华抗生物 HKIG BIOSCIENCES —— 华抗免疫技术 HKIG Immune Technology

Antibody discovery,
engineered with precision.

Part of HKIG BIOSCIENCES, HKIG Immune Technology supports biopharmaceutical companies and research institutes worldwide across the full early-discovery chain — murine monoclonal antibody discovery, antibody characterisation, humanisation, recombinant antibody & protein expression, and affinity evaluation. Built on 45 years of monoclonal antibody expertise from the Chinese Academy of Sciences.

Antibody Discovery Antibody Engineering Immune Detection

Technology platform	Timeline	Library size / throughput	HC–LC pairing	Strengths	Limitations
Hybridoma technology	3–6 months	~3,000 clones	Native	Classic and reliable; high affinity; natural in vivo immune maturation	Requires animal immunisation; low fusion efficiency; long cycle
Phage display	1–3 months	>10¹⁰	Non-native	In vitro selection; no species restriction; fully human antibodies accessible	Non-native heavy/light chain pairing; requires additional validation
Single B-cell cloning	2–4 weeks	100–10,000 clones	Native	High throughput; preserves natural diversity; functional screening moved upstream	High technical barrier; depends on single-cell sorting instrumentation
Yeast display	2–4 months	10⁷–10⁹	Non-native	FACS-compatible; well suited to affinity maturation	Smaller library than phage display; requires specialist expertise
AI-driven design	Weeks	In silico screening	N/A	Rapid candidate identification; structure-guided optimisation	Still evolving; accuracy depends on training data
HKIG technology strategy	45–55 days to clone delivery	Hybridoma core, plus single B-cell & phage display	Native	Next-generation high-efficiency hybridoma as the core platform, inheriting 45 years of CAS antibody development experience	Immunisation and screening strategies tailored per project — one stop from antigen design to candidate molecule delivery

Technology platform

Timeline

Library size / throughput

HC–LC pairing

Strengths

Limitations

Hybridoma technology

3–6 months

~3,000 clones

Native

Classic and reliable; high affinity; natural in vivo immune maturation

Requires animal immunisation; low fusion efficiency; long cycle

Phage display

1–3 months

>10¹⁰

Non-native

In vitro selection; no species restriction; fully human antibodies accessible

Non-native heavy/light chain pairing; requires additional validation

Single B-cell cloning

2–4 weeks

100–10,000 clones

Native

High throughput; preserves natural diversity; functional screening moved upstream

High technical barrier; depends on single-cell sorting instrumentation

Yeast display

2–4 months

10⁷–10⁹

Non-native

FACS-compatible; well suited to affinity maturation

Smaller library than phage display; requires specialist expertise

AI-driven design

Weeks

In silico screening

N/A

Rapid candidate identification; structure-guided optimisation

Still evolving; accuracy depends on training data

HKIG technology strategy

45–55 days to clone delivery

Hybridoma core, plus single B-cell & phage display

Native

Next-generation high-efficiency hybridoma as the core platform, inheriting 45 years of CAS antibody development experience

Immunisation and screening strategies tailored per project — one stop from antigen design to candidate molecule delivery

Antibody Drug Early Discovery

45–55 days

From antigen immunisation and hybridoma generation to characterisation, humanisation and key residue analysis — a complete discovery loop delivering clones, sequences and affinity data.

Murine mAb discovery 45–55 d

Immunisation, cell fusion, hybridoma banking, antibody preparation and affinity verification. Delivered as 5–500 clones, >80% viability, 2 vials per clone.

Antibody characterisation

Sanger sequencing of full variable region incl. signal peptide with IMGT analysis; protein affinity (ELISA EC₅₀) and cell affinity (cCLIA).

Murine antibody humanisation 14 d

Proprietary AI model for humanisation design. ≥1 clone with affinity not inferior to the parent murine antibody; humanness >90%.

Key residue analysis

Epitope key residues (28 d) and CDR key residues (21 d) mapped by ELISA — a structural basis for affinity maturation and engineering.

Deliverables: hybridoma cell lines, antibody samples (0.1 mg/clone; 5 mg per designated antibody), variable-region sequences, ELISA / cCLIA affinity data.
Quality: SDS-PAGE (reduced) >90%, SEC-HPLC >90%, endotoxin <1 EU/mg.
You provide: target protein (we can prepare it on your behalf).

Recombinant Antibody Expression & Production

3–18 days

From variable-region gene synthesis and vector construction to transient expression, affinity purification and release testing — for both monospecific and bispecific antibodies, in HEK293 or CHO mammalian cells.

Workflow: gene synthesis → vector construction → plasmid preparation & QC → transient transfection → cell culture & supernatant harvest → affinity chromatography → QC release.
Gene synthesis: 7 days for VH/VL <400 bp; 7–10 days for >400 bp.
Deliverables: expression plasmid, recombinant antibody, and a Technical Report.
Optional: lyophilisation & aliquoting, secondary purification, custom constant-region engineering, lower endotoxin limits.

Antibody Affinity Evaluation

3–4 business days

High-sensitivity affinity assessment performed directly on non-purified expression supernatant — no purification step required. Ideal for rapid ranking and triage of candidate molecules, including bispecific formats.

Protein affinity: concentration–binding curve with EC₅₀; 1–10 antibodies per assay batch.
Cell affinity: confirms recognition of conformational epitopes on the native cell surface.
One-stop option: expression + affinity testing combined, 10–14 days.
You provide: expression supernatant, target protein / cells (can be prepared on your behalf).

Recombinant Protein Expression

3–4 weeks

Prokaryotic and eukaryotic expression systems, selected according to the structural complexity, post-translational modification requirements and downstream application of your target protein.

E. coli (prokaryotic): no glycosylation; suited to structurally simple proteins and antigen peptides.
HEK293 (eukaryotic): native glycosylation and folding; suited to membrane-protein ectodomains and complex conformational antigens.
Quality: SDS-PAGE >90%, SEC-HPLC >90%; deliverables include the recombinant protein and a Technical Report.

Delivery quantity	Timeline	Typical application
≥ 1 mg	10–14 days	Activity screening, affinity evaluation, epitope analysis
≥ 10 mg	10–14 days	In vitro functional assays, cell-level activity confirmation
≥ 20 mg	10–14 days	Cell & in vitro efficacy evaluation, batch testing
≥ 50 mg	14–16 days	Mouse in vivo efficacy & pharmacokinetic pilot studies
≥ 100 mg	16–18 days	In vivo efficacy studies, preclinical preparation

Delivery quantity

Timeline

Typical application

≥ 1 mg

10–14 days

Activity screening, affinity evaluation, epitope analysis

≥ 10 mg

10–14 days

In vitro functional assays, cell-level activity confirmation

≥ 20 mg

10–14 days

Cell & in vitro efficacy evaluation, batch testing

≥ 50 mg

14–16 days

Mouse in vivo efficacy & pharmacokinetic pilot studies

≥ 100 mg

16–18 days

In vivo efficacy studies, preclinical preparation

Delivery quantity	Timeline	Typical application
≥ 0.2 mg	3–7 days	Expressibility assessment, activity screening
≥ 2 mg	3–7 days	In vitro binding & functional confirmation
≥ 4 mg	3–7 days	Cell-level efficacy evaluation
≥ 10 mg	6–10 days	Batch testing, in vivo pilot studies
≥ 20 mg	10–14 days	In vivo efficacy studies

Delivery quantity

Timeline

Typical application

≥ 0.2 mg

3–7 days

Expressibility assessment, activity screening

≥ 2 mg

3–7 days

In vitro binding & functional confirmation

≥ 4 mg

3–7 days

Cell-level efficacy evaluation

≥ 10 mg

6–10 days

Batch testing, in vivo pilot studies

≥ 20 mg

10–14 days

In vivo efficacy studies

Test item	Acceptance criterion	Method
Antibody purity (reduced)	> 90%	SDS-PAGE
Antibody monomer purity	> 90%	SEC-HPLC
Endotoxin	< 1 EU/mg	Limulus amoebocyte lysate (LAL)
Recombinant protein purity	> 90%	SDS-PAGE / SEC-HPLC
Supernatant antibody concentration	Quantitative report	Quantitative assay
Affinity	EC₅₀ determination	Concentration–binding curve fitting

Test item

Acceptance criterion

Method

Antibody purity (reduced)

> 90%

SDS-PAGE

Antibody monomer purity

> 90%

SEC-HPLC

Endotoxin

< 1 EU/mg

Limulus amoebocyte lysate (LAL)

Recombinant protein purity

> 90%

SDS-PAGE / SEC-HPLC

Supernatant antibody concentration

Quantitative report

Quantitative assay

Affinity

EC₅₀ determination

Concentration–binding curve fitting

Antibody discovery,engineered with precision.

A trusted partner in antibody discovery and antibody engineering

Our Mission

Focus

Innovation

Reliable

Five established routes to antibody discovery — and how we choose

Functional clones recovered per screening round

Our strategy: speed without compromising native pairing

PreciScreen®

One integrated service chain — four modules

Antibody Drug Early Discovery

Murine mAb discovery 45–55 d

Antibody characterisation

Murine antibody humanisation 14 d

Key residue analysis

Recombinant Antibody Expression & Production

Antibody Affinity Evaluation

Recombinant Protein Expression

Monospecific antibody — delivery tiers

Bispecific antibody — delivery tiers

From antigen to candidate molecule — with defined gates

Murine monoclonal antibody discovery

Antigen immunisation

Cell fusion

Hybridoma banking

Antibody preparation

Affinity verification

Variable-region sequencing

Candidate delivery

Recombinant antibody expression & purification

Gene synthesis

Vector construction

Plasmid prep & QC

Transient transfection

Cell culture

Affinity purification

QC & release

One-stop programme: expression + affinity evaluation

Gene synthesis & vector build

Transfection & supernatant

Affinity testing

Data analysis & delivery

A single quality standard, applied to every deliverable

Expressibility assessed first

Transparent reporting

Flexible by design

Standard deliverables

45-year technology heritage

45–55 day discovery cycle

Truly one-stop

AI-driven humanisation

Documented QC gates

Supernatant-ready assays

Where our services create value

Therapeutic antibody discovery

Humanisation & affinity maturation

Epitope mapping & competition analysis

Diagnostic antibody & IVD development

Recombinant antigen & protein supply

Material for preclinical studies

Therapeutic antibody modalities — approved products

Start a conversation

HKIG Immune Technology — WeChat

Project enquiry

Antibody discovery,
engineered with precision.

PreciScreen^®